A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications
Phase 2
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/04/024915
- Lead Sponsor
- Max Super Speciality Hospital A Unit of Devki Devi Foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients admitted with RT-PCR confirmed COVID-19 illness.
2. Age > 18 years
3. Written informed consent
4. Has any of the two
a. PaO2/ FiO2 <300
b. Respiratory Rate > 24/min and SaO2 < 93% on room air
Exclusion Criteria
1. Pregnant women
2. Breastfeeding women
3. Known hypersensitivity to blood products
4. Receipt of Pooled Immunoglobulin in last 30 days
6. Participating in any other clinical trial
7. Clinical status precluding infusion of blood products
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method